AMH Cannot Be Meaningfully Increased in Infertility Patients—Focus on Optimizing Treatment Based on Existing Levels
AMH is a marker of ovarian reserve, not a modifiable treatment target; attempting to "increase" AMH fundamentally misunderstands its biological role as a reflection of the existing primordial follicle pool, which cannot be expanded through medical intervention.
Understanding AMH's Role
AMH is produced exclusively by granulosa cells of pre-antral and small antral follicles 1. It serves as:
- A quantitative marker of the remaining ovarian follicle pool
- An indicator of ovarian reserve quality
- A predictor of response to ovarian stimulation
The primordial follicle pool is established before birth and progressively declines throughout reproductive life—no intervention can reverse this biological reality.
Why AMH Cannot Be "Increased" in a Clinically Meaningful Way
The evidence demonstrates that AMH reflects, rather than determines, fertility potential:
- AMH measures what exists, not what can be created: The hormone level correlates with the number of remaining follicles 2, 3
- Temporary fluctuations are not true increases: In one case of hypogonadotropic hypogonadism, AMH rose from 0.20 to 1.26 ng/mL during gonadotropin treatment, but this reflected stimulation of existing FSH-responsive follicles, not creation of new primordial follicles 2
- AMH only reflects the growing follicular pool responsive to gonadotropins, not the underlying primordial pool 2
The Correct Clinical Approach: Use AMH to Guide Treatment Selection
Instead of attempting to increase AMH, use existing levels to optimize fertility treatment:
For Low AMH (<1 ng/mL):
- Expect reduced natural conception rates (adjusted HR 0.77) 4
- Consider more aggressive treatment earlier rather than prolonged expectant management
- Anticipate lower response to ovarian stimulation 5
- Counsel regarding realistic expectations and potential need for donor eggs
For Normal AMH (1-5.5 ng/mL):
- Agonist protocols yield significantly more high-quality embryos compared to antagonist protocols 5
- Natural conception remains reasonable with appropriate timing
- Standard IUI protocols appropriate for unexplained infertility
For High AMH (>5.5 ng/mL, particularly >8.5 ng/mL):
- Use antagonist protocols to reduce OHSS risk 5
- Higher pregnancy rates with antagonist protocols in this population (p=0.04) 5
- Monitor for PCOS features, as AMH levels are significantly elevated in PCOS 1
For PCOS with CC Resistance:
- AMH >4.5 ng/mL predicts better OI/IUI outcomes (sensitivity 56%, specificity 69%) 6
- Consider this threshold when counseling about treatment success probability
- AMH serves as an independent predictor of pregnancy (OR 1.151) 6
Critical Clinical Pitfalls
Do not waste time with unproven interventions claiming to "boost" AMH—these delay appropriate evidence-based fertility treatment during a time-sensitive window. The biological clock cannot be reset.
AMH >2.1 ng/mL predicts significantly higher IUI success (20.0% vs 10.0% for AMH <2.1 ng/mL) 7, making this a useful threshold for treatment planning rather than a target to achieve.
The Bottom Line for Treatment Planning
Use AMH as a prognostic tool to:
- Set realistic expectations with patients
- Select appropriate stimulation protocols
- Determine urgency of treatment escalation
- Counsel regarding alternative options (donor eggs, adoption) when appropriate
The goal is not to increase AMH, but to maximize pregnancy success with the ovarian reserve that exists.